Updated: RA Capital and SoftBank head up the latest nine-figure crossover, this time for Ventus. Will an IPO soon follow?
A biotech previously backed by Versant and GV is unveiling its newest financing round, coming with a slate of blue-chip investors that could signal an IPO in the near future.
Ventus Therapeutics closed a $140 million Series C on Wednesday morning, a round led by the second SoftBank Vision Fund and RA Capital. The biotech said in a press release the money will largely be used to scale its second platform and help push its lead drug program closer to the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.